Author: "Holtzmann, Jérôme" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Holtzmann, Jérôme"' showing total 38 results

Start Over Author "Holtzmann, Jérôme"

38 results on '"Holtzmann, Jérôme"'

1. Adherence to clinical practice guidelines for using electroconvulsive therapy in elderly depressive patients

Author: Yrondi, Antoine, Blanc, Olivier, Anguill, Loic, Arbus, Christophe, Boudieu, Ludivine, Patoz, Marie-Camille, Arnould, Adeline, Charpeaud, Thomas, Genty, Jean-Baptiste, Abidine, Racan, Redon, Maximilien, Rey, Romain, Aouizerate, Bruno, Bennabi, Djamila, El-Hage, Wissam, Etain, Bruno, Holtzmann, Jérôme, Leboyer, Marion, Molière, Fanny, Richieri, Raphaelle Marie, Stéphan, Florian, Vaiva, Guillaume, Sauvaget, Anne, Poulet, Emmanuel, Haffen, Emmanuel, Courtet, Philippe, Fossati, Philippe, Llorca, Pierre-Michel, and Samalin, Ludovic
Published: 2024
Full Text: View/download PDF

2. Indirect effect of impulsivity on suicide risk through self-esteem and depressive symptoms in a population with treatment-resistant depression: A FACE-DR study

Author: Salles, Juliette, Stephan, Florian, Molière, Fanny, Bennabi, Djamila, Haffen, Emmanuel, Bouvard, Alexandra, Walter, Michel, Allauze, Etienne, Llorca, Pierre Michel, Genty, Jean Baptiste, Leboyer, Marion, Holtzmann, Jérôme, Nguon, Anne Sophie, D'Amato, Thierry, Rey, Romain, Horn, Mathilde, Vaiva, Guillaume, Fond, Guillaume, Richieri, Raphaelle, Hennion, Vincent, Etain, Bruno, El-Hage, Wissam, Camus, Vincent, Courtet, Philippe, Aouizerate, Bruno, and Yrondi, Antoine
Published: 2024
Full Text: View/download PDF

3. Long-term benzodiazepine prescription in treatment-resistant depression: A national FACE-TRD prospective study

Author: Fond, Guillaume, Faugere, Mélanie, Boyer, Laurent, Peri, Pauline, Stephan, Florian, Moliere, Fanny, Anguill, Loic, Bennabi, Djamila, Haffen, Emmanuel, Bouvard, Alexandra, Walter, Michel, Samalin, Ludovic, Llorca, Pierre Michel, Genty, Jean Baptiste, Leboyer, Marion, Holtzmann, Jérôme, Nguon, Anne Sophie, Rey, Romain, Horn, Mathilde, Vaiva, Guillaume, Hennion, Vincent, Etain, Bruno, El-Hage, Wissam, Camus, Vincent, Courtet, Philippe, Aouizerate, Bruno, Yrondi, Antoine, Lancon, Christophe, and Richieri, Raphaelle
Published: 2023
Full Text: View/download PDF

4. Diurnal symptoms of sleepiness and dysfunction predict future suicidal ideation in a French cohort of outpatients (FACE-DR) with treatment resistant depression: A 1-year prospective study about sleep markers

Author: Maruani, Julia, Molière, Fanny, Godin, Ophelia, Yrondi, Antoine, Bennabi, Djamila, Richieri, Raphaelle, El-Hage, Wissan, Allauze, Etienne, Anguill, Loic, Bouvard, Alexandra, Camus, Vincent, Dorey, Jean-Michel, Etain, Bruno, Fond, Guillaume, Genty, Jean-Baptiste, Haffen, Emmanuel, Holtzmann, Jérôme, Horn, Mathilde, Kazour, François, Nguon, Anne-Sophie, Petrucci, Jean, Rey, Romain, Stephan, Florian, Vaiva, Guillaume, Walter, Michel, Lejoyeux, Michel, Leboyer, Marion, Llorca, Pierre-Michel, Courtet, Philippe, Aouizerate, Bruno, and Geoffroy, Pierre A.
Published: 2023
Full Text: View/download PDF

5. Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort

Author: Korchia, Théo, Faugere, Mélanie, Suc, Nicolas, Garosi, Alexandra, Andrieu-Haller, Christelle, Breyton, Martin, Godin, Ophélia, Aouizerate, Bruno, Arbus, Christophe, Bennabi, Djamila, Bellivier, Frank, Bougerol, Thierry, Camus, Vincent, Courtet, Philippe, Doumy, Olivier, El-Hage, Wissam, Genty, Jean-Baptiste, Haffen, Emmanuel, Holtzmann, Jérome, Horn, Mathilde, Leboyer, Marion, Llorca, Pierre-Michel, Maruani, Julia, Moirand, Rémi, Moliere, Fanny, Petrucci, Jean, Rey, Romain, Samalin, Ludovic, Stephan, Florian, Vaiva, Guillaume, Walter, Michel, Yrondi, Antoine, Boyer, Laurent, Lancon, Christophe, Richieri, Raphaelle, and Fond, Guillaume
Published: 2022
Full Text: View/download PDF

6. Childhood Trauma increases suicidal behaviour in a treatment-resistant depression population: a FACE-DR report

Author: Aouizerate, B., Bennabi, D., Leboyer, M., Haffen, E., Llorca, P.M., Barteau, V., Bensalem, S., Laouamri, H., Souryis, Karmene, Mallet, L., Yon, L., Petrucci, J., Genty, J.B., Yrondi, A., Pierre, D., Schmitt, L., Sarrail, M., Bennabi, Djamila, Ryff, I., Beuchet, E., Tio, G., Cappe, C., Clerc, E., Garnier, M., Honciuc, R.M., Allauze, E., Blanc, O., Bellivier, F., Allaili, N., Nieto, I., Meheust, J., Sunthavy, Y., Maruani, J., Bougerol, T., Polosan, M., Courvoisier, P., Holtzmann, J., Fredembach, B., Foubert-Andreani, S., Camus, V., El Hage, W., D’Amato, T., Haesebaert, F., Dubien, C., Lefebvre, M., Meznad, A., Brunelin, J., Moirand, R., Doumy, O., Lancon, C., Richieri, R., Peri, P., Faugere, M., Faget-Agius, C., Courtet, P., Boulenger, J.P., Moliere, F., Stephan, F., Walter, M., Mesmeur, C., Vaiva, G., Horn, M., Yrondi, Antoine, Vaiva, Guillaume, Walter, Michel, D Amato, Thierry, Bellivier, Frank, Bougerol, Thierry, Camus, Vincent, Doumy, Olivier, Genty, Jean-Baptiste, Haffen, Emmanuel, Holtzmann, Jérôme, Horn, Mathilde, Lançon, Christophe, Leboyer, Marion, Llorca, Pierre-Michel, Maruani, Julia, Moirand, Rémi, Molière, Fanny, Petrucci, Jean, Richieri, Raphaelle, Samalin, Ludovic, Schmitt, Laurent, Stephan, Florian, Courtet, Philippe, El-Hage, Wissam, and Aouizerate, Bruno
Published: 2021
Full Text: View/download PDF

7. Short- and long-term efficacy of electroconvulsive stimulation in animal models of depression: The essential role of neuronal survival

Author: Jonckheere, Julie, Deloulme, Jean-Christophe, Dall’Igna, Gaëlle, Chauliac, Nicolas, Pelluet, Albane, Nguon, Anne-Sophie, Lentini, Celia, Brocard, Jacques, Denarier, Eric, Brugière, Sabine, Couté, Yohann, Heinrich, Christophe, Porcher, Christophe, Holtzmann, Jérôme, Andrieux, Annie, Suaud-Chagny, Marie-Françoise, and Gory-Fauré, Sylvie
Published: 2018
Full Text: View/download PDF

8. Evolution of Cognitive Impairments in Treatment-Resistant Depression: Results from the Longitudinal French Centers of Expertise for Treatment-Resistant Depression (FACE-DR) Cohort

Author: Vancappel, Alexis, primary, Dansou, Yecodji, additional, Godin, Ophelia, additional, Haffen, Emmanuel, additional, Yrondi, Antoine, additional, Stephan, Florian, additional, Richieri, Raphaelle Marie, additional, Molière, Fanny, additional, Holtzmann, Jérôme, additional, Horn, Mathilde, additional, Allauze, Etienne, additional, Genty, Jean Baptiste, additional, Bouvard, Alex, additional, Dorey, Jean-Michel, additional, Hennion, Vincent, additional, Camus, Vincent, additional, Fond, Guillaume, additional, Peran, Barbara, additional, Walter, Michel, additional, Anguill, Loic, additional, Scotto D’apolina, Charlotte, additional, Vilà, Estelle, additional, Fredembach, Benjamin, additional, Petrucci, Jean, additional, Rey, Romain, additional, Nguon, Anne Sophie, additional, Etain, Bruno, additional, Carminati, Mathilde, additional, Courtet, Philippe, additional, Vaiva, Guillaume, additional, Llorca, Pierre Michel, additional, Leboyer, Marion, additional, Aouizerate, Bruno, additional, Bennabi, Djamila, additional, and El Hage, Wissam, additional
Published: 2023
Full Text: View/download PDF

9. Dépression résistante : les stratégies de potentialisation

Author: Doumy, Olivier, Bennabi, Djamila, El-Hage, Wissam, Allaïli, Najib, Bation, Rémy, Bellivier, Frank, Holtzmann, Jérôme, Bubrovszky, Maxime, Camus, Vincent, Charpeaud, Thomas, Courvoisier, Pierre, d’Amato, Thierry, Garnier, Marion, Haesebaert, Frédéric, Bougerol, Thierry, Lançon, Christophe, Moliere, Fanny, Nieto, Isabel, Richieri, Raphaëlle, Saba, Ghassen, Courtet, Philippe, Vaiva, Guillaume, Leboyer, Marion, Llorca, Pierre-Michel, Aouizerate, Bruno, and Haffen, Emmanuel
Published: 2016
Full Text: View/download PDF

10. Dépression résistante : les autres stratégies thérapeutiques

Author: Saba, Ghassen, Nieto, Isabel, Bation, Rémy, Allaïli, Najib, Bennabi, Djamila, Moliere, Fanny, Richieri, Raphaëlle, Holtzmann, Jérôme, Bubrovszky, Maxime, Camus, Vincent, Charpeaud, Thomas, Courtet, Philippe, Courvoisier, Pierre, Haesebaert, Frédéric, Doumy, Olivier, El-Hage, Wissam, Garnier, Marion, d’Amato, Thierry, Bougerol, Thierry, Lançon, Christophe, Haffen, Emmanuel, Llorca, Pierre-Michel, Vaiva, Guillaume, Bellivier, Frank, Leboyer, Marion, and Aouizerate, Bruno
Published: 2016
Full Text: View/download PDF

11. Dépression résistante : les stratégies de changement et d’association de médicaments antidépresseurs

Author: Charpeaud, Thomas, Moliere, Fanny, Bubrovszky, Maxime, Haesebaert, Frédéric, Allaïli, Najib, Bation, Rémy, Nieto, Isabel, Richieri, Raphaëlle, Saba, Ghassen, Bellivier, Frank, Bennabi, Djamila, Holtzmann, Jérôme, Camus, Vincent, Courtet, Philippe, Courvoisier, Pierre, d’Amato, Thierry, Doumy, Olivier, Garnier, Marion, Bougerol, Thierry, Lançon, Christophe, Haffen, Emmanuel, Leboyer, Marion, Llorca, Pierre-Michel, Vaiva, Guillaume, El-Hage, Wissam, and Aouizerate, Bruno
Published: 2016
Full Text: View/download PDF

12. Quelle définition pour la dépression résistante ?

Author: Holtzmann, Jérôme, Richieri, Raphaëlle, Saba, Ghassen, Allaïli, Najib, Bation, Rémy, Moliere, Fanny, Nieto, Isabel, Bellivier, Frank, Bennabi, Djamila, Bubrovszky, Maxime, Camus, Vincent, Charpeaud, Thomas, Courvoisier, Pierre, Haesebaert, Frédéric, Doumy, Olivier, Courtet, Philippe, El-Hage, Wissam, Garnier, Marion, d’Amato, Thierry, Lançon, Christophe, Leboyer, Marion, Llorca, Pierre-Michel, Vaiva, Guillaume, Bougerol, Thierry, Aouizerate, Bruno, and Haffen, Emmanuel
Published: 2016
Full Text: View/download PDF

13. Effect of sleep disturbance symptoms on treatment outcome in blended CBT for depression: A secondary analysis of the E-COMPARED study. (Preprint)

Author: Jensen, Esben Skov, Ladegaard, Nicolai, Mellentin, Angelina Isabella, Ebert, David Daniel, Titzler, Ingrid, Baltra, Ricardo Araya, Cerga-Pahoja, Arlinda, Hazo, Jean-Baptiste, Holtzmann, Jérôme, Cieslak, Roman, Smoktunowicz, Ewelina, Rivera, Rosa Maria Baños, Herrero, Rocio, García-Palacios, Azucena, Botella, Cristina, Berger, Thomas, Krieger, Tobias, Holmberg, Trine Theresa, Topooco, Naira, Andersson, Gerhard, van Straten, Annemieke, Kemmern, Lise, Kleiboer, Annet, Riper, Heleen, and Mathiasen, Kim
Subjects: 610 Medicine & health
Abstract: Background: Sleep disturbance symptoms are common in major depressive disorder (MDD) and have been found to hamper the treatment effect of conventional face-to-face psychological treatments such as cognitive behavioral therapy. To increase the dissemination of evidence-based treatment, blended cognitive behavioral therapy (bCBT) consisting of web-based and face-to-face treatment is on the rise for patients with MDD. To date, no study has examined whether sleep disturbance symptoms have an impact on bCBT treatment outcomes and whether it affects bCBT and treatment-as-usual (TAU) equally. Objective: The objectives of this study are to investigate whether baseline sleep disturbance symptoms have an impact on treatment outcomes independent of treatment modality and whether sleep disturbance symptoms impact bCBT and TAU in routine care equally. Methods: The study was based on data from the E-COMPARED (European Comparative Effectiveness Research on Blended Depression Treatment Versus Treatment-as-Usual) study, a 2-arm, multisite, parallel randomized controlled, noninferiority trial. A total of 943 outpatients with MDD were randomized to either bCBT (476/943, 50.5%) or TAU consisting of routine clinical MDD treatment (467/943, 49.5%). The primary outcome of this study was the change in depression symptom severity at the 12-month follow-up. The secondary outcomes were the change in depression symptom severity at the 3- and 6-month follow-up and MDD diagnoses at the 12-month follow-up, assessed using the Patient Health Questionnaire-9 and Mini-International Neuropsychiatric Interview, respectively. Mixed effects models were used to examine the association of sleep disturbance symptoms with treatment outcome and treatment modality over time. Results: Of the 943 patients recruited for the study, 558 (59.2%) completed the 12-month follow-up assessment. In the total sample, baseline sleep disturbance symptoms did not significantly affect change in depressive symptom severity at the 12-month follow-up (β=.16, 95% CI –0.04 to 0.36). However, baseline sleep disturbance symptoms were negatively associated with treatment outcome for bCBT (β=.49, 95% CI 0.22-0.76) but not for TAU (β=–.23, 95% CI −0.50 to 0.05) at the 12-month follow-up, even when adjusting for baseline depression symptom severity. The same result was seen for the effect of sleep disturbance symptoms on the presence of depression measured with Mini-International Neuropsychiatric Interview at the 12-month follow-up. However, for both treatment formats, baseline sleep disturbance symptoms were not associated with depression symptom severity at either the 3- (β=.06, 95% CI −0.11 to 0.23) or 6-month (β=.09, 95% CI −0.10 to 0.28) follow-up. Conclusions: Baseline sleep disturbance symptoms may have a negative impact on long-term treatment outcomes in bCBT for MDD. This effect was not observed for TAU. These findings suggest that special attention to sleep disturbance symptoms might be warranted when MDD is treated with bCBT. Future studies should investigate the effect of implementing modules specifically targeting sleep disturbance symptoms in bCBT for MDD to improve long-term prognosis.
Published: 2022
Full Text: View/download PDF

14. Effect of sleep disturbance symptoms on treatment outcome in blended CBT for depression: A secondary analysis of the E-COMPARED study

Author: Jensen, Esben Skov, Ladegaard, Nicolai, Mellentin, Angelina Isabella, Ebert, David Daniel, Titzler, Ingrid, Araya, Ricardo, Cerga Pahoja, Arlinda, Hazo, Jean-Baptiste, Holtzmann, Jérôme, Cieslak, Roman, Smoktunowicz, Ewelina, Baños, Rosa, Herrero, Rocio, García-Palacios, Azucena, Botella, Cristina, Berger, Thomas, Krieger, Tobias, Holmberg, Trine Theresa, Topooco, Naira, Andersson, Gerhard, van Straten, Annemieke, Kemmern, Lise, Kleiboer, Annet, Riper, Heleen, and Mathiasen, Kim
Subjects: 610 Medicine & health
Abstract: Background: Sleep disturbance symptoms are common in major depressive disorder (MDD) and have been found to hamper the treatment effect of conventional face-to-face psychological treatments such as cognitive behavioral therapy. To increase the dissemination of evidence-based treatment, blended cognitive behavioral therapy (bCBT) consisting of web-based and face-to-face treatment is on the rise for patients with MDD. To date, no study has examined whether sleep disturbance symptoms have an impact on bCBT treatment outcomes and whether it affects bCBT and treatment-as-usual (TAU) equally. Objective: The objectives of this study are to investigate whether baseline sleep disturbance symptoms have an impact on treatment outcomes independent of treatment modality and whether sleep disturbance symptoms impact bCBT and TAU in routine care equally. Methods: The study was based on data from the E-COMPARED (European Comparative Effectiveness Research on Blended Depression Treatment Versus Treatment-as-Usual) study, a 2-arm, multisite, parallel randomized controlled, noninferiority trial. A total of 943 outpatients with MDD were randomized to either bCBT (476/943, 50.5%) or TAU consisting of routine clinical MDD treatment (467/943, 49.5%). The primary outcome of this study was the change in depression symptom severity at the 12-month follow-up. The secondary outcomes were the change in depression symptom severity at the 3- and 6-month follow-up and MDD diagnoses at the 12-month follow-up, assessed using the Patient Health Questionnaire-9 and Mini-International Neuropsychiatric Interview, respectively. Mixed effects models were used to examine the association of sleep disturbance symptoms with treatment outcome and treatment modality over time. Results: Of the 943 patients recruited for the study, 558 (59.2%) completed the 12-month follow-up assessment. In the total sample, baseline sleep disturbance symptoms did not significantly affect change in depressive symptom severity at the 12-month follow-up (β=.16, 95% CI –0.04 to 0.36). However, baseline sleep disturbance symptoms were negatively associated with treatment outcome for bCBT (β=.49, 95% CI 0.22-0.76) but not for TAU (β=–.23, 95% CI −0.50 to 0.05) at the 12-month follow-up, even when adjusting for baseline depression symptom severity. The same result was seen for the effect of sleep disturbance symptoms on the presence of depression measured with Mini-International Neuropsychiatric Interview at the 12-month follow-up. However, for both treatment formats, baseline sleep disturbance symptoms were not associated with depression symptom severity at either the 3- (β=.06, 95% CI −0.11 to 0.23) or 6-month (β=.09, 95% CI −0.10 to 0.28) follow-up. Conclusions: Baseline sleep disturbance symptoms may have a negative impact on long-term treatment outcomes in bCBT for MDD. This effect was not observed for TAU. These findings suggest that special attention to sleep disturbance symptoms might be warranted when MDD is treated with bCBT. Future studies should investigate the effect of implementing modules specifically targeting sleep disturbance symptoms in bCBT for MDD to improve long-term prognosis.
Published: 2022
Full Text: View/download PDF

15. A Data-Driven Clustering Method for Discovering Profiles in the Dynamics of Major Depressive Disorder Using a Smartphone-Based Ecological Momentary Assessment of Mood

Author: van Genugten, Claire R., primary, Schuurmans, Josien, additional, Hoogendoorn, Adriaan W., additional, Araya, Ricardo, additional, Andersson, Gerhard, additional, Baños, Rosa M., additional, Berger, Thomas, additional, Botella, Cristina, additional, Cerga Pashoja, Arlinda, additional, Cieslak, Roman, additional, Ebert, David D., additional, García-Palacios, Azucena, additional, Hazo, Jean-Baptiste, additional, Herrero, Rocío, additional, Holtzmann, Jérôme, additional, Kemmeren, Lise, additional, Kleiboer, Annet, additional, Krieger, Tobias, additional, Rogala, Anna, additional, Titzler, Ingrid, additional, Topooco, Naira, additional, Smit, Johannes H., additional, and Riper, Heleen, additional
Published: 2022
Full Text: View/download PDF

16. Examining the Theoretical Framework of Behavioral Activation for Major Depressive Disorder: Smartphone-Based Ecological Momentary Assessment Study

Author: van Genugten, Claire Rosalie, primary, Schuurmans, Josien, additional, Hoogendoorn, Adriaan W, additional, Araya, Ricardo, additional, Andersson, Gerhard, additional, Baños, Rosa, additional, Botella, Cristina, additional, Cerga Pashoja, Arlinda, additional, Cieslak, Roman, additional, Ebert, David Daniel, additional, García-Palacios, Azucena, additional, Hazo, Jean-Baptiste, additional, Herrero, Rocío, additional, Holtzmann, Jérôme, additional, Kemmeren, Lise, additional, Kleiboer, Annet, additional, Krieger, Tobias, additional, Smoktunowicz, Ewelina, additional, Titzler, Ingrid, additional, Topooco, Naira, additional, Urech, Antoine, additional, Smit, Johannes H, additional, and Riper, Heleen, additional
Published: 2021
Full Text: View/download PDF

17. Occurrence of Side Effects in Treatment-Resistant Depression: Role of Clinical, Socio-Demographic and Environmental Characteristics

Author: Levy, Anna, primary, El-Hage, Wissam, additional, Bennabi, Djamila, additional, Allauze, Etienne, additional, Bouvard, Alexandra, additional, Camus, Vincent, additional, Courtet, Philippe, additional, Dorey, Jean-Michel, additional, Etain, Bruno, additional, Fond, Guillaume, additional, Genty, Jean-Baptiste, additional, Holtzmann, Jérôme, additional, Horn, Mathilde, additional, Leboyer, Marion, additional, Llorca, Pierre-Michel, additional, Meyrel, Manon, additional, Molière, Fanny, additional, Nguon, Anne-Sophie, additional, Petrucci, Jean, additional, Rey, Romain, additional, Richieri, Raphaelle, additional, Stephan, Florian, additional, Vaiva, Guillaume, additional, Walter, Michel, additional, Haffen, Emmanuel, additional, Aouizerate, Bruno, additional, and Yrondi, Antoine, additional
Published: 2021
Full Text: View/download PDF

18. Examining the Theoretical Framework of Behavioral Activation for Major Depressive Disorder: Smartphone-Based Ecological Momentary Assessment Study (Preprint)

Author: van Genugten, Claire Rosalie, primary, Schuurmans, Josien, additional, Hoogendoorn, Adriaan W, additional, Araya, Ricardo, additional, Andersson, Gerhard, additional, Baños, Rosa, additional, Botella, Cristina, additional, Cerga Pashoja, Arlinda, additional, Cieslak, Roman, additional, Ebert, David Daniel, additional, García-Palacios, Azucena, additional, Hazo, Jean-Baptiste, additional, Herrero, Rocío, additional, Holtzmann, Jérôme, additional, Kemmeren, Lise, additional, Kleiboer, Annet, additional, Krieger, Tobias, additional, Smoktunowicz, Ewelina, additional, Titzler, Ingrid, additional, Topooco, Naira, additional, Urech, Antoine, additional, Smit, Johannes H, additional, and Riper, Heleen, additional
Published: 2021
Full Text: View/download PDF

19. Effect of Sleep Disturbance Symptoms on Treatment Outcome in Blended Cognitive Behavioral Therapy for Depression (E-COMPARED Study): Secondary Analysis (Preprint)

Author: Jensen, Esben Skov, primary, Ladegaard, Nicolai, additional, Mellentin, Angelina Isabella, additional, Ebert, David Daniel, additional, Titzler, Ingrid, additional, Araya, Ricardo, additional, Cerga Pashoja, Arlinda, additional, Hazo, Jean-Baptiste, additional, Holtzmann, Jérôme, additional, Cieslak, Roman, additional, Smoktunowicz, Ewelina, additional, Baños, Rosa, additional, Herrero, Rocio, additional, García-Palacios, Azucena, additional, Botella, Cristina, additional, Berger, Thomas, additional, Krieger, Tobias, additional, Holmberg, Trine Theresa, additional, Topooco, Naira, additional, Andersson, Gerhard, additional, van Straten, Annemieke, additional, Kemmeren, Lise, additional, Kleiboer, Annet, additional, Riper, Heleen, additional, and Mathiasen, Kim, additional
Published: 2021
Full Text: View/download PDF

20. Effect of sleep disturbance symptoms on treatment outcome in blended CBT for depression: A secondary analysis of the E-COMPARED study. (Preprint)

Author: Jensen, Esben Skov, primary, Ladegaard, Nicolai, additional, Mellentin, Angelina Isabella, additional, Ebert, David Daniel, additional, Titzler, Ingrid, additional, Baltra, Ricardo Araya, additional, Cerga-Pahoja, Arlinda, additional, Hazo, Jean-Baptiste, additional, Holtzmann, Jérôme, additional, Cieslak, Roman, additional, Smoktunowicz, Ewelina, additional, Rivera, Rosa Maria Baños, additional, Herrero, Rocio, additional, García-Palacios, Azucena, additional, Botella, Cristina, additional, Berger, Thomas, additional, Krieger, Tobias, additional, Holmberg, Trine Theresa, additional, Topooco, Naira, additional, Andersson, Gerhard, additional, van Straten, Annemieke, additional, Kemmern, Lise, additional, Kleiboer, Annet, additional, Riper, Heleen, additional, and Mathiasen, Kim, additional
Published: 2021
Full Text: View/download PDF

21. Childhood Trauma increases suicidal behaviour in a treatment-resistant depression population: a FACE-DR report

Author: Yrondi, Antoine, primary, Vaiva, Guillaume, additional, Walter, Michel, additional, D Amato, Thierry, additional, Bellivier, Frank, additional, Bennabi, Djamila, additional, Bougerol, Thierry, additional, Camus, Vincent, additional, Doumy, Olivier, additional, Genty, Jean-Baptiste, additional, Haffen, Emmanuel, additional, Holtzmann, Jérôme, additional, Horn, Mathilde, additional, Lançon, Christophe, additional, Leboyer, Marion, additional, Llorca, Pierre-Michel, additional, Maruani, Julia, additional, Moirand, Rémi, additional, Molière, Fanny, additional, Petrucci, Jean, additional, Richieri, Raphaelle, additional, Samalin, Ludovic, additional, Schmitt, Laurent, additional, Stephan, Florian, additional, Courtet, Philippe, additional, El-Hage, Wissam, additional, Aouizerate, Bruno, additional, Aouizerate, B., additional, Bennabi, D., additional, Leboyer, M., additional, Haffen, E., additional, Llorca, P.M., additional, Barteau, V., additional, Bensalem, S., additional, Laouamri, H., additional, Souryis, Karmene, additional, Mallet, L., additional, Yon, L., additional, Petrucci, J., additional, Genty, J.B., additional, Yrondi, A., additional, Pierre, D., additional, Schmitt, L., additional, Sarrail, M., additional, Ryff, I., additional, Beuchet, E., additional, Tio, G., additional, Cappe, C., additional, Clerc, E., additional, Garnier, M., additional, Honciuc, R.M., additional, Allauze, E., additional, Blanc, O., additional, Bellivier, F., additional, Allaili, N., additional, Nieto, I., additional, Meheust, J., additional, Sunthavy, Y., additional, Maruani, J., additional, Bougerol, T., additional, Polosan, M., additional, Courvoisier, P., additional, Holtzmann, J., additional, Fredembach, B., additional, Foubert-Andreani, S., additional, Camus, V., additional, El Hage, W., additional, D’Amato, T., additional, Haesebaert, F., additional, Dubien, C., additional, Lefebvre, M., additional, Meznad, A., additional, Brunelin, J., additional, Moirand, R., additional, Doumy, O., additional, Lancon, C., additional, Richieri, R., additional, Peri, P., additional, Faugere, M., additional, Faget-Agius, C., additional, Courtet, P., additional, Boulenger, J.P., additional, Moliere, F., additional, Stephan, F., additional, Walter, M., additional, Mesmeur, C., additional, Vaiva, G., additional, and Horn, M., additional
Published: 2021
Full Text: View/download PDF

22. Treatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort

Author: Yrondi, Antoine, primary, Bennabi, Djamila, additional, Haffen, Emmanuel, additional, Quelard, Delphine, additional, Samalin, Ludovic, additional, Maruani, Julia, additional, Allauze, Etienne, additional, Pierre, Damien, additional, Bougerol, Thierry, additional, Camus, Vincent, additional, D’Amato, Thierry, additional, Doumy, Olivier, additional, Holtzmann, Jérôme, additional, Lançon, Christophe, additional, Moliere, Fanny, additional, Moirand, Rémi, additional, Nieto, Isabel, additional, Richieri, Raphaëlle, additional, Horn, Mathilde, additional, Schmitt, Laurent, additional, Stephan, Florian, additional, Genty, Jean-Baptiste, additional, Vaiva, Guillaume, additional, Walter, Michel, additional, Courtet, Philippe, additional, Leboyer, Marion, additional, Llorca, Pierre-Michel, additional, Marguet, Sophie, additional, Dennis, Nathalie, additional, Schaetz, Dominique, additional, El-Hage, Wissam, additional, and Aouizerate, Bruno, additional
Published: 2020
Full Text: View/download PDF

23. Association between anhedonia and suicidal events in patients with mood disorders: A 3‐year prospective study

Author: Ducasse, Déborah, primary, Dubois, Jonathan, additional, Jaussent, Isabelle, additional, Azorin, Jean‐Michel, additional, Etain, Bruno, additional, Gard, Sébastien, additional, Henry, Chantal, additional, Bougerol, Thierry, additional, Kahn, Jean‐Pierre, additional, Aubin, Valérie, additional, Bellivier, Frank, additional, Belzeaux, Raoul, additional, Dubertret, Caroline, additional, Dubreucq, Julien, additional, Llorca, Pierre‐Michel, additional, Loftus, Josephine, additional, Passerieux, Christine, additional, Polosan, Mircea, additional, Samalin, Ludovic, additional, Leboyer, Marion, additional, Yrondi, Antoine, additional, Bennabi, Djamila, additional, Haffen, Emmanuel, additional, Maruani, Julia, additional, Allauze, Etienne, additional, Camus, Vincent, additional, D'Amato, Thierry, additional, Doumy, Olivier, additional, Holtzmann, Jérôme, additional, Lançon, Christophe, additional, Moliere, Fanny, additional, Moirand, Rémi, additional, Richieri, Raphaëlle Marie, additional, Horn, Mathilde, additional, Schmitt, Laurent, additional, Stephan, Florian, additional, Genty, Jean‐Baptiste, additional, Vaiva, Guillaume, additional, Walter, Michel, additional, El‐Hage, Wissam, additional, Aouizerate, Bruno, additional, Olié, Emilie, additional, and Courtet, Philippe, additional
Published: 2020
Full Text: View/download PDF

24. Relationship between Childhood Physical Abuse and Clinical Severity of Treatment-Resistant Depression in a Geriatric Population

Author: Yrondi, Antoine, primary, Arbus, Christophe, additional, Bennabi, Djamila, additional, D'Amato, Thierry, additional, Bellivier, Frank, additional, Bougerol, Thierry, additional, Camus, Vincent, additional, Courtet, Philippe, additional, Doumy, Olivier, additional, Genty, Jean Baptiste, additional, Holtzmann, Jérôme, additional, Horn, Mathilde, additional, Lancon, Christophe, additional, Leboyer, Marion, additional, Llorca, Pierre-Michel, additional, Maruani, Julia, additional, Moirand, Rémi, additional, Molière, Fanny, additional, Petrucci, Jean, additional, Richieri, Raphaelle, additional, Samalin, Ludovic, additional, Stephan, Florian, additional, Vaiva, Guillaume, additional, Walter, Michel, additional, Haffen, Emmanuel, additional, Aouizerate, Bruno, additional, and El-Hage, Wissam, additional
Published: 2020
Full Text: View/download PDF

25. Using the Personalized Advantage Index for Individual Treatment Allocation to Blended Treatment or Treatment as Usual for Depression in Secondary Care

Author: Friedl, Nadine, primary, Krieger, Tobias, additional, Chevreul, Karine, additional, Hazo, Jean Baptiste, additional, Holtzmann, Jérôme, additional, Hoogendoorn, Mark, additional, Kleiboer, Annet, additional, Mathiasen, Kim, additional, Urech, Antoine, additional, Riper, Heleen, additional, and Berger, Thomas, additional
Published: 2020
Full Text: View/download PDF

26. Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression

Author: Godin, Ophelia, Bennabi, Djamila, Yrondi, Antoine, Richieri, Raphaëlle, D’amato, Thierry, Bellivier, Franck, Bougerol, Thierry, Horn, Mathilde, Camus, Vincent, Courtet, Philippe, Doumy, Olivier, Genty, Jean Baptiste, El-Hage, Wissam, Haesebaert, Frédéric, Holtzmann, Jérôme, Lançon, Christophe, Leboyer, Marion, Llorca, Pierre Michel, Maruani, Julia, Moliere, Fanny, Samalin, Ludovic, Schmitt, Laurent, Stéphan, Florian, Vaiva, Guillaume, Walter, Michel, Aouizerate, Bruno, Haffen, Emmanuel, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Fondation FondaMental [Créteil], Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre Hospitalier le Vinatier [Bron], Neurobiologie et Psychiatrie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire [Grenoble] (CHU), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), CHU Toulouse [Toulouse], Hopital de Bohars - CHRU Brest (CHU - BREST ), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Charles Perrens, Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Centre hospitalier Charles Perrens [Bordeaux]
Subjects: [SCCO]Cognitive science, Prevalence of metabolic syndrome (MetS), [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Treatment-resistant depression (TRD)
Abstract: International audience; BACKGROUND:The aim of this study was to estimate the prevalence of metabolic syndrome (MetS) and its components in a cohort of French patients with treatment-resistant depression (TRD) and to determine correlations with sociodemographic, clinical, and treatment-related factors.METHODS:From 2012 to 2018, 205 patients who met DSM-IV criteria for major depressive episode with moderate-to-severe symptoms (Montgomery-Asberg Depression Rating Scale score ≥ 20), and at least Stage II resistance according to Thase and Rush criteria were enrolled in the FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) cohort. Data on sociodemographic and clinical characteristics, lifestyle information, and treatment and comorbidities were collected, and a blood sample was drawn. MetS was defined according to the criteria of the International Diabetes Federation.RESULTS:Overall, 38% of individuals with TRD met criteria for MetS. The frequency of MetS was significantly higher in men than in women only for patients aged 40 years or older (46.3% vs 35.2%, P = .0427). Moreover, whereas the management for diabetes was good, less than one-third of the patients with high blood pressure or dyslipidemia were treated for these conditions. Multivariate analysis showed that individuals with abnormal plasma c-reactive protein levels had a 3-fold increased risk (95% CI, 1.5-5.2) of having MetS, independent of other potential confounders.CONCLUSION:The prevalence of MetS is higher in patients with TRD than in those with other psychiatric disorders and characterized by a considerable undertreatment of some components of MetS in this population. Diagnosis and treatment of the components of MetS should be systematically performed to prevent the occurrence of cardiovascular diseases in patients with TRD. These findings highlight the need for integrated care, with more interaction and coordination between psychiatrists and primary care providers.
Published: 2019
Full Text: View/download PDF

27. Relationship between childhood physical abuse and clinical severity of treatment-resistant depression in a geriatric population.

Author: Yrondi, Antoine, Arbus, Christophe, Bennabi, Djamila, D'Amato, Thierry, Bellivier, Frank, Bougerol, Thierry, Camus, Vincent, Courtet, Philippe, Doumy, Olivier, Genty, Jean-Baptiste, Holtzmann, Jérôme, Horn, Mathilde, Lancon, Christophe, Leboyer, Marion, Llorca, Pierre-Michel, Maruani, Julia, Moirand, Rémi, Molière, Fanny, Petrucci, Jean, and Richieri, Raphaelle
Subjects: PHYSICAL abuse, MENTAL depression, CHILD abuse, SELF-esteem
Abstract: Introduction: We assessed the correlation between childhood maltreatment (CM) and severity of depression in an elderly unipolar Treatment-Resistant Depression (TRD) sample. Methods: Patients were enrolled from a longitudinal cohort (FACE-DR) of the French Network of Expert TRD Centres. Results: Our sample included 96 patients (33% of the overall cohort) aged 60 years or above, with a mean age of 67.2 (SD = 5.7). The majority of the patients were female (62.5%). The Montgomery and Asberg Depression Rating Scale (MADRS) and Quick Inventory Depression Scale-Self Report (QIDS-SR) mean scores were high, 28.2 (SD = 7.49) [MADRS score range: 0–60; moderate severity≥20, high severity≥35] and 16.5 (SD = 4.94) [IDS-SR score range: 0–27; moderate severity≥11, high severity≥16], respectively. Mean self-esteem scores were 22.47 (SD = 6.26) [range 0–30]. In an age- and sex-adjusted model, we found a positive correlation between childhood trauma (CTQ scores) and depressive symptom severity [MADRS (β = 0.274; p = 0.07) and QIDS-SR (β = 0.302; p = 0.005) scores]. We detected a statistically significant correlation between physical abuse and depressive symptom severity [MADRS (β = 0.304; p = 0.03) and QIDS-SR (β = 0.362; p = 0.005) scores]. We did not observe any significant correlation between other types of trauma and depressive symptom severity. We showed that self-esteem (Rosenberg scale) mediated the effect of physical abuse (PA) on the intensity of depressive symptoms [MADRS: b = 0.318, 95% BCa C.I. [0.07, 0.62]; QIDS-SR: b = 0.177, 95% BCa C.I. [0.04, 0.37]]. Preacher & Kelly's Kappa Squared values of 19.1% (k2 = 0.191) and 16% (k2 = 0.16), respectively for the two scales, indicate a moderate effect. Conclusion: To our knowledge, this is the first study conducted in a geriatric TRD population documenting an association between childhood trauma (mainly relating to PA) and the intensity of depressive symptoms. [ABSTRACT FROM AUTHOR]
Published: 2021
Full Text: View/download PDF

28. Significant Need for a French Network of Expert Centers Enabling a Better Characterization and Management of Treatment-Resistant Depression (Fondation FondaMental)

Author: Yrondi, Antoine, Bennabi, Djamila, Haffen, Emmanuel, Garnier, Marion, Bellivier, Frank, Bourgerol, Thierry, Camus, Vincent, D'Amato, Thierry, Doumy, Olivier, Haesebaert, Frédéric, Holtzmann, Jérôme, Lançon, Christophe, Vignaud, Philippe, Moliere, Fanny, Nieto, Isabel, Richieri, Raphaelle, Domenech, Philippe, Rabu, Corentin, Mallet, Luc, Yon, Liova, Schmitt, Laurent, Stephan, Florian, Vaiva, Guillaume, Walter, Michel, Llorca, Pierre-Michel, Courtet, Philippe, Leboyer, Marion, El-Hage, Wissam, Aouizerate, Bruno, Toulouse Neuro Imaging Center (ToNIC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation FondaMental [Créteil], Imagerie et cerveau, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle de psychiatrie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-CHU Marseille, Département de neurosciences (CHU Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor, Oxalya, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service Psychiatrie et psychologie médicale [CHU Purpan], CHU Toulouse [Toulouse], Laboratoire de Neurosciences de Brest (LNB), Université de Brest (UBO), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Ethique, Professionalisme et Santé (JE 2535-EPS), Université de Brest (UBO)-Institut des Sciences de l'Homme et de la Société - ISHS, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Science et Technologie du Lait et de l'Oeuf (STLO), Institut National de la Recherche Agronomique (INRA)-AGROCAMPUS OUEST, Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Clermont-Ferrand, Centre Hospitalier Universitaire [Grenoble] (CHU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier le Vinatier [Bron], Hôpital Charles Perrens, Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] (Hôpitaux Sud), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Université Lumière - Lyon 2 (UL2), Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Hopital de Bohars - CHRU Brest (CHU - BREST ), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Hôpital Henri Mondor, Clinique Psychiatrique Universitaire [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de psychiatrie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Institut des Sciences Cognitives (ISC), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Image, Ville, Environnement (LIVE), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), CHRU Brest - Psychiatrie Adulte (CHU - Brest- Psychiatrie), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-CHU Clermont-Ferrand, Fondation Fondamental, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre hospitalier Charles Perrens [Bordeaux], Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants (SPMC), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Neurologie et thérapeutique expérimentale, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), El-Hage, Wissam, Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), UNIROUEN - UFR Santé, Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Pôle de Psychiatrie 'Solaris', Service Pr. Naudin, Centre Hospitalier Universitaire de Sainte-Marguerite, Département de neurosciences ( CHU Henri Mondor ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière ( CRICM ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Lumière - Lyon 2 ( UL2 ), Laboratoire de Neurosciences de Brest ( LNB ), Université de Brest ( UBO ), Laboratoire de Neurosciences Fonctionnelles et Pathologies ( LNFP ), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique ( CNRS ), Ethique, Professionalisme et Santé ( JE 2535-EPS ), Université de Brest ( UBO ) -Institut des Sciences de l'Homme et de la Société - ISHS, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne ( NPsy-Sydo ), CHU Clermont-Ferrand-Université Clermont Auvergne ( UCA ), Pathologies du système nerveux : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -IFR76-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, CHRU Tours, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, UMR U 1253, Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], UMR 7362, Laboratoire Image, Ville, Environnement [Strasbourg] (LIVE), Université de Strasbourg (UNISTRA)-Université de Strasbourg (UNISTRA), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Douhairie, Marie-Laurence, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR70-Université Pierre et Marie Curie - Paris 6 (UPMC), and Guedj, Eric
Subjects: lcsh:RC435-571, assessment, [SDV]Life Sciences [q-bio], [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, depressive disorder, lcsh:Psychiatry, Clinical Study Protocol, ComputingMilieux_MISCELLANEOUS, Psychiatry, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SCCO.NEUR]Cognitive science/Neuroscience, [SCCO.NEUR] Cognitive science/Neuroscience, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, innovative strategies, [SDV] Life Sciences [q-bio], [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [ SCCO.NEUR ] Cognitive science/Neuroscience, treatment-resistant depression, network, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background Major depression is characterized by (i) a high lifetime prevalence of 16–17% in the general population; (ii) a high frequency of treatment resistance in around 20–30% of cases; (iii) a recurrent or chronic course; (iv) a negative impact on the general functioning and quality of life; and (v) a high level of comorbidity with various psychiatric and non-psychiatric disorders, high occurrence of completed suicide, significant burden along with the personal, societal, and economic costs. In this context, there is an important need for the development of a network of expert centers for treatment-resistant depression (TRD), as performed under the leadership of the Fondation FondaMental. Methods The principal mission of this national network is to establish a genuine prevention, screening, and diagnosis policy for TRD to offer a systematic, comprehensive, longitudinal, and multidimensional evaluation of cases. A shared electronic medical file is used referring to a common exhaustive and standardized set of assessment tools exploring psychiatric, non-psychiatric, metabolic, biological, and cognitive dimensions of TRD. This is paralleled by a medico-economic evaluation to examine the global economic burden of the disease and related health-care resource utilization. In addition, an integrated biobank has been built by the collection of serum and DNA samples for the measurement of several biomarkers that could further be associated with the treatment resistance in the recruited depressed patients. A French observational long-term follow-up cohort study is currently in progress enabling the extensive assessment of resistant depressed patients. In those unresponsive cases, each expert center proposes relevant therapeutic options that are classically aligned to the international guidelines referring to recognized scientific societies. Discussion This approach is expected to improve the overall clinical assessments and to provide evidence-based information to those clinicians most closely involved in the management of TRD thereby facilitating treatment decisions and choice in everyday clinical practice. This could contribute to significantly improve the poor prognosis, the relapsing course, daily functioning and heavy burden of TRD. Moreover, the newly created French network of expert centers for TRD will be particularly helpful for a better characterization of sociodemographic, clinical, neuropsychological, and biological markers of treatment resistance required for the further development of personalized therapeutic strategies in TRD.
Published: 2017
Full Text: View/download PDF

29. Evaluation Of A Blended Cbt Platform For Depression Through Mixed Methods : A Clinical Trial And Qualitative Evaluation From Psychotherapists

Author: Picot-Ngo, Clément, Hazo, Jean-Baptiste, Michel, Morgane, Daval, Laure, Prigent, Amélie, Holtzmann, Jérôme, Titzler, Ingrid, and Ebert, David
Abstract: As part of the E-COMPARED project, we conducted an experiment on the Moodbusteru00ae platform which provides web-based cognitivo-behavioural therapy (CBT) modules for major depressive disorder. These modules are blended with face-to-face CBT sessions.Our first aim was to assess the clinical and cost-effectiveness of such blended CBT compared to traditional CBT.The second objective was to analyse professional feedbacks about Moodbusteru00ae and the principle of blended therapy of the therapists involved in the project.A two-arm randomized controlled trial was carried out in 10 specialized major depression centres. Adult patients who meet DSM-IV criteria for MDD were included either in the blended CBT arm, mixing 8 face-to-face sessions with Moodbusteru00ae modules, or in the control group, consisting in 18 sessions of face-to-face CBT. The depressive symptoms, quality of life and healthcare consumption information have been taken at baseline, post-treatment and 12 months.10 therapists involved in both arms of the protocol were interviewed afterward with a semi-structured interview grid. Their answers were thematically categorised and analysed by two researchers.Quantitative analyses showed either inferiority or non-inferiority of blended CBT vs traditional one in terms of cost and clinical effectiveness, depending of the outcome and time of measurement. Qualitative results provide the advantages, limiting factors and perspectives of improvement of the blended therapy.As designed in Moodbusteru00ae and in this trial, blended CBT seems not as efficient as face-to-face therapy but feedback from therapists and, in the future, users are prone to improve their results.
Published: 2017

30. Childhood maltreatment and clinical severity of treatment-resistant depression in a French cohort of outpatients (FACE-DR): One-year follow-up.

Author: Yrondi, Antoine, Aouizerate, Bruno, Bennabi, Djamila, Richieri, Raphaëlle, D'Amato, Thierry, Bellivier, Frank, Bougerol, Thierry, Horn, Mathilde, Camus, Vincent, Courtet, Philippe, Doumy, Olivier, Genty, Jean B., Holtzmann, Jérôme, Lancon, Christophe, Leboyer, Marion, Llorca, Pierre M., Maruani, Julia, Moirand, Remi, Molière, Fanny, and Samalin, Ludovic
Subjects: MENTAL depression, PHYSICAL abuse, SEX crimes, PSYCHOLOGICAL child abuse, ABUSE of older people
Abstract: Background: Childhood maltreatment is associated with major depressive disorder (MDD). It not only increases the risk of lifetime MDD, but it also aggravates its course. Among depressed patients, 20-30% of them experience treatment-resistance depression (TRD). We aimed to assess the association between childhood maltreatment, severity of depression in a unipolar TRD sample, and patient outcomes after one-year of follow-up.Methods: Patients were recruited for a prospective cohort from the French network of TRD expert centers. Depressive symptom severity was assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology self-report (QIDS-SR). Childhood maltreatment was evaluated with the Childhood Trauma Questionnaire (CTQ).Results: In total, 256 patients filled in the CTQ at baseline between 2012 and 2019. At baseline, the MADRS score was associated with CTQ score (β = .185; p = .004). QIDS was also associated with CTQ scores (β = .27; p < .001). Regarding the different subtypes of childhood maltreatment, MADRS was associated with physical (β = .21; p = .005) and sexual abuse (β = .22; p = .002), while QIDS with physical abuse (β = .304; p < .001) and physical neglect (β = .254; p < .001). However, we did not find any significant association focusing on the other types of traumas. During a 1-year follow-up focusing on remission, CTQ scores (baseline) were less important in remittent patients [n = 38; CTQ score = 39.26 (9.68)] than in nonremittent ones [n = 92; CTQ score = 46.02 (17.53)] (p = .027). There was no significant difference among remitters and nonremitters based on trauma subtypes. At baseline, CTQ scores had a significant influence on remission at 1 year (χ2 (1) = 5.57; p < .05). We lost this influence adding MADRS scores at baseline in the model (p = .063).Conclusion: We highlighted a significant association between the severity of depressive disorders and childhood maltreatment in the TRD population. Information about a history of childhood maltreatment helps in identifying individuals who could be less likely to go into remission after treatment. [ABSTRACT FROM AUTHOR]
Published: 2020
Full Text: View/download PDF

31. Effect of Sleep Disturbance Symptoms on Treatment Outcome in Blended Cognitive Behavioral Therapy for Depression (E-COMPARED Study): Secondary Analysis.

Author: Jensen, Esben Skov, Ladegaard, Nicolai, Mellentin, Angelina Isabella, Ebert, David Daniel, Titzler, Ingrid, Araya, Ricardo, Pashoja, Arlinda Cerga, Hazo, Jean-Baptiste, Holtzmann, Jérôme, Cieslak, Roman, Smoktunowicz, Ewelina, Baños, Rosa, Herrero, Rocio, García-Palacios, Azucena, Botella, Cristina, Berger, Thomas, Krieger, Tobias, Holmberg, Trine Theresa, Topooco, Naira, and Andersson, Gerhard
Abstract: Background: Sleep disturbance symptoms are common in major depressive disorder (MDD) and have been found to hamper the treatment effect of conventional face-to-face psychological treatments such as cognitive behavioral therapy. To increase the dissemination of evidence-based treatment, blended cognitive behavioral therapy (bCBT) consisting of web-based and face-to-face treatment is on the rise for patients with MDD. To date, no study has examined whether sleep disturbance symptoms have an impact on bCBT treatment outcomes and whether it affects bCBT and treatment-as-usual (TAU) equally.Objective: The objectives of this study are to investigate whether baseline sleep disturbance symptoms have an impact on treatment outcomes independent of treatment modality and whether sleep disturbance symptoms impact bCBT and TAU in routine care equally.Methods: The study was based on data from the E-COMPARED (European Comparative Effectiveness Research on Blended Depression Treatment Versus Treatment-as-Usual) study, a 2-arm, multisite, parallel randomized controlled, noninferiority trial. A total of 943 outpatients with MDD were randomized to either bCBT (476/943, 50.5%) or TAU consisting of routine clinical MDD treatment (467/943, 49.5%). The primary outcome of this study was the change in depression symptom severity at the 12-month follow-up. The secondary outcomes were the change in depression symptom severity at the 3- and 6-month follow-up and MDD diagnoses at the 12-month follow-up, assessed using the Patient Health Questionnaire-9 and Mini-International Neuropsychiatric Interview, respectively. Mixed effects models were used to examine the association of sleep disturbance symptoms with treatment outcome and treatment modality over time.Results: Of the 943 patients recruited for the study, 558 (59.2%) completed the 12-month follow-up assessment. In the total sample, baseline sleep disturbance symptoms did not significantly affect change in depressive symptom severity at the 12-month follow-up (β=.16, 95% CI -0.04 to 0.36). However, baseline sleep disturbance symptoms were negatively associated with treatment outcome for bCBT (β=.49, 95% CI 0.22-0.76) but not for TAU (β=-.23, 95% CI -0.50 to 0.05) at the 12-month follow-up, even when adjusting for baseline depression symptom severity. The same result was seen for the effect of sleep disturbance symptoms on the presence of depression measured with Mini-International Neuropsychiatric Interview at the 12-month follow-up. However, for both treatment formats, baseline sleep disturbance symptoms were not associated with depression symptom severity at either the 3- (β=.06, 95% CI -0.11 to 0.23) or 6-month (β=.09, 95% CI -0.10 to 0.28) follow-up.Conclusions: Baseline sleep disturbance symptoms may have a negative impact on long-term treatment outcomes in bCBT for MDD. This effect was not observed for TAU. These findings suggest that special attention to sleep disturbance symptoms might be warranted when MDD is treated with bCBT. Future studies should investigate the effect of implementing modules specifically targeting sleep disturbance symptoms in bCBT for MDD to improve long-term prognosis. [ABSTRACT FROM AUTHOR]
Published: 2022
Full Text: View/download PDF

32. Esketamine-induced post-traumatic stress disorder flashbacks during treatment-resistant depression indication: is it just a side effect?

Author: Rothärmel M, Mekaoui L, Kazour F, Herrero M, Beetz-Lobono EM, Lengvenyte A, Holtzmann J, Raynaud P, Cuenca M, Bulteau S, de Maricourt P, Husson T, Olié E, Gohier B, Sauvaget A, Gaillard R, Richieri R, Szekely D, Samalin L, Guillin O, Moulier V, El-Hage W, Laurin A, and Berkovitch L
Abstract: Background: Posttraumatic stress disorder (PTSD) is a severe and frequent affection that is highly comorbid to major depressive disorder. Comorbid PTSD and depression are usually treatment-resistant, with a high risk of functional impairment and suicide. Esketamine nasal spray is a recent validated treatment for treatment-resistant depression (TRD), but its efficacy on comorbid TRD-PTSD remains insufficiently documented. In particular, flashbacks can occur during esketamine administration and their influence on clinical outcomes is unknown., Objectives: Our main objective was to describe esketamine-induced traumatic flashbacks and their impact on clinical trajectories within a sample of patients with comorbid TRD-PTSD., Methods: We retrospectively collected clinical data of patients receiving esketamine nasal spray for TRD with comorbid PTSD who experienced at least one flashback of their trauma during esketamine sessions across 11 psychiatric departments., Results: Between February 2020 and March 2023, 22 adult patients with TRD met inclusion criteria. In sixteen patients (72.7%) flashbacks disappeared as the sessions progressed. In six patients (27.3%), esketamine treatment was stopped because of persistent flashbacks. When esketamine was continued, clinical response was observed both for depression and PTSD (depression response rate: 45.5% and remission rate: 22.7%; PTSD response rate: 45.5% and remission: 18.2%)., Limitations: The retrospective design of the study and the absence of a comparator group are the main limitations of our study., Conclusions: Our results suggest that the occurrence of esketamine-induced traumatic flashbacks does not hinder clinical response. On the contrary, when managed appropriately and combined with targeted psychotherapy, it could even contribute to positive outcomes., Competing Interests: Conflict of interest Most of the authors of this article received honoraria or consulting fees from Janssen-Cilag (MR, LM, MH, JH, SB, MD, EO, BG, AS, RG, RR, DZ, LS, OG, AL, LB) with no financial or other relationship relevant to the subject of this article.
Published: 2024
Full Text: View/download PDF

33. Association between anhedonia and suicidal events in patients with mood disorders: A 3-year prospective study.

Author: Ducasse D, Dubois J, Jaussent I, Azorin JM, Etain B, Gard S, Henry C, Bougerol T, Kahn JP, Aubin V, Bellivier F, Belzeaux R, Dubertret C, Dubreucq J, Llorca PM, Loftus J, Passerieux C, Polosan M, Samalin L, Leboyer M, Yrondi A, Bennabi D, Haffen E, Maruani J, Allauze E, Camus V, D'Amato T, Doumy O, Holtzmann J, Lançon C, Moliere F, Moirand R, Richieri RM, Horn M, Schmitt L, Stephan F, Genty JB, Vaiva G, Walter M, El-Hage W, Aouizerate B, Olié E, and Courtet P
Subjects: Humans, Mood Disorders epidemiology, Prospective Studies, Risk Factors, Suicide, Attempted, Anhedonia, Suicidal Ideation
Abstract: Background: As almost all mental disorders are associated with increased suicidal-related behavior, anhedonia might be a trans-diagnostic dimension to target for suicide prevention., Methods: For this 3-year-long prospective study, 2,839 outpatients with mood disorders were recruited. They were divided in: (a) two groups according to the occurrence or not of suicidal ideation during the follow-up, and (b) two groups according to the occurrence or not of suicide attempts during the follow-up. Anhedonia was assessed using a composite score (the French version of the 14-item Snaith-Hamilton Pleasure Scale and item 13 of the Quick Inventory of Depressive Symptomatology scale) at inclusion and at 6, 12, 24, and 36 months after inclusion., Results: Patients with mood disorders and anhedonia at least at one follow-up visit had a 1.4-fold higher risk of suicidal ideation (adjusted odds ratio = 1.35; 95% confidence interval [1.07, 1.70]), even after adjustment for confounding factors of suicide risk (i.e., bipolar or unipolar disorder, sex, age, marital status, education level, antidepressant intake, personal history of suicide attempt, at least one childhood trauma, and mean of the maximum depression score during the follow-up). Conversely, association between anhedonia and suicide attempt did not remain significant after adjustment., Conclusions: The significant association between anhedonia and suicide ideation in patients with mood disorders stresses the need of targeting hedonia in mood disorders, and of research focusing on the position to pleasure in life through eudaimonia., (© 2020 Wiley Periodicals LLC.)
Published: 2021
Full Text: View/download PDF

34. Significant Need for a French Network of Expert Centers Enabling a Better Characterization and Management of Treatment-Resistant Depression (Fondation FondaMental).

Author: Yrondi A, Bennabi D, Haffen E, Garnier M, Bellivier F, Bourgerol T, Camus V, D'Amato T, Doumy O, Haesebaert F, Holtzmann J, Lançon C, Vignaud P, Moliere F, Nieto I, Richieri RM, Domenech P, Rabu C, Mallet L, Yon L, Schmitt L, Stephan F, Vaiva G, Walter M, Llorca PM, Courtet P, Leboyer M, El-Hage W, and Aouizerate B
Abstract: Background: Major depression is characterized by (i) a high lifetime prevalence of 16-17% in the general population; (ii) a high frequency of treatment resistance in around 20-30% of cases; (iii) a recurrent or chronic course; (iv) a negative impact on the general functioning and quality of life; and (v) a high level of comorbidity with various psychiatric and non-psychiatric disorders, high occurrence of completed suicide, significant burden along with the personal, societal, and economic costs. In this context, there is an important need for the development of a network of expert centers for treatment-resistant depression (TRD), as performed under the leadership of the Fondation FondaMental., Methods: The principal mission of this national network is to establish a genuine prevention, screening, and diagnosis policy for TRD to offer a systematic, comprehensive, longitudinal, and multidimensional evaluation of cases. A shared electronic medical file is used referring to a common exhaustive and standardized set of assessment tools exploring psychiatric, non-psychiatric, metabolic, biological, and cognitive dimensions of TRD. This is paralleled by a medico-economic evaluation to examine the global economic burden of the disease and related health-care resource utilization. In addition, an integrated biobank has been built by the collection of serum and DNA samples for the measurement of several biomarkers that could further be associated with the treatment resistance in the recruited depressed patients. A French observational long-term follow-up cohort study is currently in progress enabling the extensive assessment of resistant depressed patients. In those unresponsive cases, each expert center proposes relevant therapeutic options that are classically aligned to the international guidelines referring to recognized scientific societies., Discussion: This approach is expected to improve the overall clinical assessments and to provide evidence-based information to those clinicians most closely involved in the management of TRD thereby facilitating treatment decisions and choice in everyday clinical practice. This could contribute to significantly improve the poor prognosis, the relapsing course, daily functioning and heavy burden of TRD. Moreover, the newly created French network of expert centers for TRD will be particularly helpful for a better characterization of sociodemographic, clinical, neuropsychological, and biological markers of treatment resistance required for the further development of personalized therapeutic strategies in TRD.
Published: 2017
Full Text: View/download PDF

35. [Switching and combining strategies of antidepressant medications].

Author: Charpeaud T, Moliere F, Bubrovszky M, Haesebaert F, Allaïli N, Bation R, Nieto I, Richieri R, Saba G, Bellivier F, Bennabi D, Holtzmann J, Camus V, Courtet P, Courvoisier P, d'Amato T, Doumy O, Garnier M, Bougerol T, Lançon C, Haffen E, Leboyer M, Llorca PM, Vaiva G, El-Hage W, and Aouizerate B
Subjects: Antidepressive Agents adverse effects, Antidepressive Agents classification, Antidepressive Agents pharmacokinetics, Drug Administration Schedule, Drug Interactions, Drug Resistance, Drug Substitution, Drug Therapy, Combination, Humans, Practice Guidelines as Topic, Antidepressive Agents therapeutic use, Depressive Disorder drug therapy
Abstract: Switching antidepressant medication may be helpful in depressed patients having no benefit from the initial antidepressant treatment. Before considering switching strategy, the initial antidepressant treatment should produce no therapeutic effect after at least 4 weeks of administration at adequate dosage. Choosing an antidepressant of pharmacologically distinct profile fails to consistently demonstrate a significant superiority in terms of effectiveness over the switching to another antidepressant within the same pharmacological class. Augmenting SSRI/SNRIs with mirtazapine/mianserin has become the most recommended strategy of antidepressant combinations. Augmenting SSRI with tricyclic drugs is now a less recommended strategy of antidepressant combinations given the increased risk for the occurrence of pharmacokinetic drug-drug interactions and adverse effects., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
Published: 2016
Full Text: View/download PDF

36. [How to define treatment-resistant depression?].

Author: Holtzmann J, Richieri R, Saba G, Allaïli N, Bation R, Moliere F, Nieto I, Bellivier F, Bennabi D, Bubrovszky M, Camus V, Charpeaud T, Courvoisier P, Haesebaert F, Doumy O, Courtet P, El-Hage W, Garnier M, d'Amato T, Lançon C, Leboyer M, Llorca PM, Vaiva G, Bougerol T, Aouizerate B, and Haffen E
Subjects: Antidepressive Agents classification, Antidepressive Agents pharmacokinetics, Antidepressive Agents therapeutic use, Avitaminosis diagnosis, Chronic Pain diagnosis, Comorbidity, Depressive Disorder classification, Depressive Disorder epidemiology, Diagnosis, Differential, Drug Interactions, Drug Resistance, Drug Substitution, Electroconvulsive Therapy, Endocrine System Diseases diagnosis, Humans, Mental Disorders diagnosis, Patient Compliance, Psychometrics, Quality of Life, Recurrence, Socioeconomic Factors, Stress, Psychological epidemiology, Stress, Psychological psychology, Depressive Disorder diagnosis
Abstract: The most largely used definition of the treatment-resistant depression relies on the failure of two successive trials of antidepressant treatment at an adequate dose and duration. The absence of response to previous antidepressant treatments should be assessed using specific and appropriate clinical instruments enabling a correct staging of the therapeutic resistance. A wide range of socio-demographic and clinical factors (i.e. psychiatric/somatic comorbidities) are classically associated with the therapeutic resistance. The aim of the treatment of major depression is to achieve a complete clinical remission. The presence of residual symptoms increases the risk for the subsequent occurrence of relapses and recurrences, hence facilitating the development of therapeutic resistance. The treatment-resistant depression has a deleterious impact on the social, familial or professional functioning, thereby leading to an impaired quality of life with serious socioeconomic consequences and costs., (Copyright © 2016. Published by Elsevier Masson SAS.)
Published: 2016
Full Text: View/download PDF

37. [Potentiation strategies].

Author: Doumy O, Bennabi D, El-Hage W, Allaïli N, Bation R, Bellivier F, Holtzmann J, Bubrovszky M, Camus V, Charpeaud T, Courvoisier P, d'Amato T, Garnier M, Haesebaert F, Bougerol T, Lançon C, Moliere F, Nieto I, Richieri R, Saba G, Courtet P, Vaiva G, Leboyer M, Llorca PM, Aouizerate B, and Haffen E
Subjects: Anticonvulsants pharmacokinetics, Anticonvulsants therapeutic use, Antidepressive Agents classification, Antidepressive Agents pharmacokinetics, Antipsychotic Agents adverse effects, Antipsychotic Agents pharmacokinetics, Antipsychotic Agents therapeutic use, Bipolar Disorder drug therapy, Double-Blind Method, Drug Resistance, Drug Synergism, Drug Therapy, Combination, Humans, Lithium Carbonate pharmacokinetics, Lithium Carbonate therapeutic use, Meta-Analysis as Topic, Practice Guidelines as Topic, Randomized Controlled Trials as Topic, Thyroid Hormones pharmacokinetics, Thyroid Hormones therapeutic use, Thyrotropin blood, Treatment Outcome, Antidepressive Agents therapeutic use, Depressive Disorder drug therapy
Abstract: Lithium is among the most classically recommended add-on therapeutic strategy for the management of depressive patients showing unsuccessful response to standard antidepressant medications. The effectiveness of the add-on strategy with lithium requires achieving plasma levels above 0.5 mEq/L. Mood-stabilizing antiepileptic drugs such as carbamazepine, valproate derivatives or lamotrigine have not demonstrated conclusive therapeutic effects for the management of depressive patients showing unsuccessful response to standard antidepressant medications. Thyroid hormones are considered among the currently recommended add-on therapeutic strategy for the management of depressive patients showing unsuccessful response to standard antidepressant medications. The effectiveness of the add-on strategy with thyroid hormones requires achieving plasma concentration of TSH close to the lower limits at the normal range (0.4 μUI/L) or even below it. Second-generation antipsychotics such as aripiprazole or quetiapine have consistently demonstrated significant therapeutic effects for the management of depressive patients showing unsuccessful response to standard antidepressant medications. Second-generation antipsychotics however require the careful monitoring of both cardiovascular and metabolic adverse effects., (Copyright © 2016. Published by Elsevier Masson SAS.)
Published: 2016
Full Text: View/download PDF

38. [Other therapeutic strategies].

Author: Saba G, Nieto I, Bation R, Allaïli N, Bennabi D, Moliere F, Richieri R, Holtzmann J, Bubrovszky M, Camus V, Charpeaud T, Courtet P, Courvoisier P, Haesebaert F, Doumy O, El-Hage W, Garnier M, d'Amato T, Bougerol T, Lançon C, Haffen E, Llorca PM, Vaiva G, Bellivier F, Leboyer M, and Aouizerate B
Subjects: Antidepressive Agents pharmacokinetics, Double-Blind Method, Drug Interactions, Drug Resistance, Drug Therapy, Combination, Fatty Acids, Omega-3 therapeutic use, Folic Acid therapeutic use, Food-Drug Interactions, Humans, Monoamine Oxidase Inhibitors pharmacokinetics, Randomized Controlled Trials as Topic, S-Adenosylmethionine therapeutic use, Adrenergic alpha-Agonists therapeutic use, Antidepressive Agents therapeutic use, Central Nervous System Stimulants therapeutic use, Depressive Disorder drug therapy, Dietary Supplements, Dopamine Agonists therapeutic use, Excitatory Amino Acid Antagonists therapeutic use, Ketamine therapeutic use, Monoamine Oxidase Inhibitors therapeutic use
Abstract: Non-selective and irreversible MAOI have become as third or fourth-line strategy for the management of treatment-resistant depression. Non-selective and irreversible MAOI requires careful monitoring of drug interactions and dietary restrictions. Nutritional supplements such as omega-3 have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment. The glutamate antagonist ketamine has been found to produce beneficial effects in the management of treatment-resistant depression while administered alone. Dopamine and/or norepinephrine agonists, such as methylphenidate, modafinil or pramipexole, have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment., (Copyright © 2016. Published by Elsevier Masson SAS.)
Published: 2016
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

38 results on '"Holtzmann, Jérôme"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources